ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet2012270-76ometendo-6553Research ArticleСтатьиArticlesОсобенности сахароснижающей терапии и контроля гликемии в период соблюдения поста РамаданFeatures of glucose lowering therapies and glycemic control during Ramadan fastingGalstyanG R-KrylovV V-ValeevaF V-MorugovaT V-GufraevaA F-20121506201292№2 (2012)7076Copyright © Galstyan G.R., Krylov V.V., Valeeva F.V., Morugova T.V., Gufraeva A.F., 20122012Galstyan G.R., Krylov V.V., Valeeva F.V., Morugova T.V., Gufraeva A.F.Galstyan G.R., Krylov V.V., Valeeva F.V., Morugova T.V., Gufraeva A.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/6553ReferencesKaramat MA, Syed A, Hanif W. Review of diabetes management and guidelines during Ramadan. J R Soc Med 2010;103:139-47.Karamat MA, Syed A, Hanif W. Review of diabetes management and guidelines during Ramadan. J R Soc Med 2010;103:139-47.Al Arouj M, Assaad-Khalil S, Buse J et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010;33:1895-902.Al Arouj M, Assaad-Khalil S, Buse J et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010;33:1895-902.Salti I, Benard E, Detournay B et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004;27:2306-11.Salti I, Benard E, Detournay B et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004;27:2306-11.Hui E, Bravis V, Hassanein M et al. Management of people with diabetes wanting to fast during Ramadan. BMJ 2010;340:c3053.Hui E, Bravis V, Hassanein M et al. Management of people with diabetes wanting to fast during Ramadan. BMJ 2010;340:c3053.Barnett AH, Cradock S, Fisher M et al. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract 2010;64:1121-9.Barnett AH, Cradock S, Fisher M et al. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract 2010;64:1121-9.Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-76.Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-76.Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909.Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909.Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008;25:245-54.Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008;25:245-54.Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health 2006;9:193-8.Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health 2006;9:193-8.Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197-202.Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197-202.Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72.Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72.Bell DS. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 2004;26:1714-27.Bell DS. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 2004;26:1714-27.Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006;55:S20-S27.Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006;55:S20-S27.van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sul-fonylureas. J Clin Epidemiol 1997;50:735-41.van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sul-fonylureas. J Clin Epidemiol 1997;50:735-41.Bodmer M, Meier C, Krahenbuhl S et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008;31:2086-91.Bodmer M, Meier C, Krahenbuhl S et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008;31:2086-91.Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002;58:45-53.Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002;58:45-53.Cesur M, Corapcioglu D, Gursoy A et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract 2007;75:141-7.Cesur M, Corapcioglu D, Gursoy A et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract 2007;75:141-7.Devendra D, Gohel B, Bravis V et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009;63: 1446-50.Devendra D, Gohel B, Bravis V et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009;63: 1446-50.The Glimepiride in Ramadan (GLIRA) Study Group. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005;28:421-2.The Glimepiride in Ramadan (GLIRA) Study Group. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005;28:421-2.Belkhadir J, El Ghomari H, Klocker N et al. Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide. BMJ 1993;307:292-5Belkhadir J, El Ghomari H, Klocker N et al. Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide. BMJ 1993;307:292-5Sari R, Balci MK, Akbas SH, et al. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res 2004;30:169-77.Sari R, Balci MK, Akbas SH, et al. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res 2004;30:169-77.Uysal AR, Erdogan MF, Sahin G et al. Clinical and metabolic effects of fasting in 41 type 2 diabetic patients during Ramadan. Diabetes Care 1998; 21:2033-4Uysal AR, Erdogan MF, Sahin G et al. Clinical and metabolic effects of fasting in 41 type 2 diabetic patients during Ramadan. Diabetes Care 1998; 21:2033-4Schernthaner G, Grimaldi A, Di Mario U et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42.Schernthaner G, Grimaldi A, Di Mario U et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42.Gonzalez-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications 2009;23:376-9.Gonzalez-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications 2009;23:376-9.Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 1996;28:426-9.Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 1996;28:426-9.Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 1998;55:563-84.Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 1998;55:563-84.Tessier D, Dawson K, Tetrault JP et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994;11:974-80.Tessier D, Dawson K, Tetrault JP et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994;11:974-80.Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989;12:203-8.Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989;12:203-8.Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005;28:2948-61.Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005;28:2948-61.MAPPING THE GLOBAL MUSLIMPOPULATION A Report on the Size and Distribution of the World'sMuslim Population October 2009 www.pewforum.org.MAPPING THE GLOBAL MUSLIMPOPULATION A Report on the Size and Distribution of the World'sMuslim Population October 2009 www.pewforum.org.Предварительные данные Всероссийской переписи населения 2010 г. www.perepis-2010.ru.Предварительные данные Всероссийской переписи населения 2010 г. www.perepis-2010.ru.Aravind S.R., Khaled Al Tayeb King Abdullah, Shaiful Bahari, Naim Shehadeh Meyer, Rose Liu, Robert Balshaw, Nadia Lesnikova,Cynthia J. Girman, Bret J. Musser, Michael J. Davies, Harvey L. Katzeff, Samuel S. Engel, Larry Radican Hypoglycaemia in type 2 diabetic patients taking sulfonylurea in Ramadan.Aravind S.R., Khaled Al Tayeb King Abdullah, Shaiful Bahari, Naim Shehadeh Meyer, Rose Liu, Robert Balshaw, Nadia Lesnikova,Cynthia J. Girman, Bret J. Musser, Michael J. Davies, Harvey L. Katzeff, Samuel S. Engel, Larry Radican Hypoglycaemia in type 2 diabetic patients taking sulfonylurea in Ramadan.Devendra D, Gohel B, Bravis V et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabe-tes patients during Ramadan. Int J Clin Pract 2009;63:1446-50.Devendra D, Gohel B, Bravis V et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabe-tes patients during Ramadan. Int J Clin Pract 2009;63:1446-50.Hassanein M, Hanif W, Malik W et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin 2011;27:1367-74.Hassanein M, Hanif W, Malik W et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin 2011;27:1367-74.
The authors declare that there are no conflicts of interest present.